Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis
- 24 July 2015
- journal article
- research article
- Published by Springer Nature in Journal of Bone and Mineral Metabolism
- Vol. 34 (5) , 540-546
Abstract
Subjects affected by thalassemia major (TM) often have reduced bone mass and increased fracture risk. Strontium ranelate (SrR) is an effective treatment for postmenopausal and male osteoporosis. To date, no data exist on the use of SrR in the treatment of TM-related osteoporosis. Our aim was to evaluate the effects of SrR on bone mineral density (BMD), bone turnover markers and inhibitors of Wnt signaling (sclerostin and DKK-1). Twenty-four TM osteoporotic women were randomized to receive daily SrR 2 g or placebo in addition to calcium carbonate (1,000 mg) and vitamin D (800 IU). BMD at the lumbar spine and femoral neck, bone turnover markers (C-terminal telopeptide of procollagen type I [CTX], bone-specific alkaline phosphatase [BSAP]) and insulin-like growth factor-1 (IGF-1), sclerostin and DKK-1 were assessed at baseline and after 24 months. Back pain was measured by visual analog scale (VAS) every 6 months. After 24 months, TM women treated with SrR had increased their spine BMD values in comparison to baseline (p < 0.05). Moreover, they also exhibited a reduction of CTX and sclerostin levels (but not DKK-1) and exhibited an increase of BSAP and IGF-1 (p < 0.05); however, no significant changes were observed in the placebo group. In the SrR group, a reduction of back pain was observed after 18 months in comparison to baseline (p < 0.05) and after 24 months in comparison to placebo (p < 0.05). Our study reports for the first time the effects of SrR in the treatment of TM-related osteoporosis. SrR treatment improved BMD and normalized bone turnover markers, as well as lowering sclerostin serum levels.Keywords
This publication has 36 references indexed in Scilit:
- Thalassemia Bone Disease: A 19-Year Longitudinal AnalysisJournal of Bone and Mineral Research, 2014
- Involvement of WNT/β-catenin Signaling in the Treatment of OsteoporosisCalcified Tissue International, 2013
- Efficacy and Safety of Strontium Ranelate in the Treatment of Osteoporosis in MenThe Journal of Clinical Endocrinology & Metabolism, 2013
- High Circulating Sclerostin is Present in Patients with Thalassemia-associated Osteoporosis and Correlates with Bone Mineral DensityHormone and Metabolic Research, 2012
- The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 yearsOsteoporosis International, 2011
- Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administrationHaematologica, 2009
- Strontium Ranelate Treatment Improves Trabecular and Cortical Intrinsic Bone Tissue Quality, a Determinant of Bone StrengthJournal of Bone and Mineral Research, 2007
- Bone Histomorphometry in Children and Adolescents with β-Thalassemia Disease: Iron-Associated Focal OsteomalaciaThe Journal of Clinical Endocrinology & Metabolism, 2003
- Bisphosphonates in the Treatment of Thalassemia-Induced OsteoporosisOsteoporosis International, 2002
- Mechanisms of Action and Therapeutic Potential of Strontium in BoneCalcified Tissue International, 2001